Trends in Continuation of Long-Acting Reversible Contraception Among Adolescents Receiving Medicaid

被引:0
作者
Allison, Bianca A. [1 ,2 ]
Ritter, Victor [3 ,4 ]
Lin, Feng-Chang [3 ]
Flower, Kori B. [2 ]
Perry, Martha F. [2 ,5 ]
机构
[1] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA
[2] Univ N Carolina, Sch Med, Dept Pediat, Div Gen Pediat & Adolescent Med, Chapel Hill, NC USA
[3] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA
[4] Stanford Sch Med, Quantitat Sci Unit, Palo Alto, CA USA
[5] Childrens Natl, Dept Pediat, Div Adolescent & Young Adult Med, Washington, DC USA
基金
美国国家卫生研究院;
关键词
Long acting reversible contraception; Adolescents; Medicaid; Subdermal implant; Intrauterine device; EXPERIENCES; EFFICACY; PROVIDER; IMPLANT; SUPPORT; SAFETY; WOMEN; BIAS; CARE;
D O I
10.1016/j.jadohealth.2024.04.029
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Purpose: Despite increasing use of long-acting reversible contraception (LARC) among U.S. adolescents, there is limited literature on factors affecting intrauterine device (IUD) or subdermal implant use. This study aimed to describe statewide rates, and associated patient and provider factors of adolescent IUD or implant initiation and continuation. Methods: This retrospective cohort study used N.C. Medicaid claims data. 10,408 adolescents were eligible (i.e., 13-19 years, female sex, continuous Medicaid enrollment, had an IUD or implant insertion or removal code from January 1, 2013, to October 1, 2015). Bivariate analyses assessed differences in adolescents using IUD versus implant. Kaplan-Meier curves were created to assess IUD or implant discontinuation through December 31, 2018. Results: Adolescents initiated 8,592 implants and 3,369 IUDs (N = 11,961). There were significant differences in nearly all provider and patient factors for those who initiated implants versus IUDs. 16% of implants and 53% of IUDs were removed in the first year. Younger (i.e., age <18 years old), Hispanic, and Black adolescents had higher adjusted continuation of implants compared with older and White adolescents, respectively (both p < .001). Those whose IUD was inserted by an obstetrician/gynecologist provider had lower continuation of IUDs compared with non-obstetrician/gynecologist providers (p < .001). Discussion: We found that age-related, racial, and ethnic disparities exist in both implant and IUD continuation. Practice changes to support positive adolescent experiences with implant and IUD insertion and removals are needed, including patient-centered health care provider training in contraception counseling, LARC initiation and removal training for adolescent-facing providers, and broader clinic capacity for LARC services. (c) 2024 Society for Adolescent Health and Medicine. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:487 / 495
页数:9
相关论文
共 49 条
[1]   Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant [J].
Ali, Moazzam ;
Akin, Ayse ;
Bahamondes, Luis ;
Brache, Vivian ;
Habib, Ndema ;
Landoulsi, Sihem ;
Hubacher, David .
HUMAN REPRODUCTION, 2016, 31 (11) :2491-2498
[2]  
American Medical Association, 2020, Healthcare provider taxonomy
[3]   "I wish they could hold on a little longer": physicians' experiences with requests for early IUD removal [J].
Amico, Jennifer R. ;
Bennett, Ariana H. ;
Karasz, Alison ;
Gold, Marji .
CONTRACEPTION, 2017, 96 (02) :106-110
[4]   "She just told me to leave it": Women's experiences discussing early elective IUD removal [J].
Amico, Jennifer R. ;
Bennett, Ariana H. ;
Karasz, Alison ;
Gold, Marji .
CONTRACEPTION, 2016, 94 (04) :357-361
[5]  
[Anonymous], North Carolina counties
[6]  
Bayer Healthcare Pharmaceuticals, 2022, Mirena (levonorgestrel-releasing intrauterine system) package insert
[7]  
Bayer Healthcare Pharmaceuticals, 2020, Mirena (levonorgestrel-releasing intrauterine system) package insert
[8]  
Bayer Healthcare Pharmaceuticals, 2017, Skyla (levonorgestrel-releasing intrauterine system) package insert
[9]  
Bayer Healthcare Pharmaceuticals, 2016, Kyleena (levonorgestrel-releasing intrauterine system) package insert
[10]   Frequency and Types of Patient-Reported Errors in Electronic Health Record Ambulatory Care Notes [J].
Bell, Sigall K. ;
Delbanco, Tom ;
Elmore, Joann G. ;
Fitzgerald, Patricia S. ;
Fossa, Alan ;
Harcourt, Kendall ;
Leveille, Suzanne G. ;
Payne, Thomas H. ;
Stametz, Rebecca A. ;
Walker, Jan ;
DesRoches, Catherine M. .
JAMA NETWORK OPEN, 2020, 3 (06)